Cargando…

1821. Evaluation of Cerebrospinal Fluid White Blood Cell Count Criteria for Use of the BioFire(®) FilmArray(®) Meningitis/Encephalitis Panel in Immunocompetent Patients

BACKGROUND: In 2016, our academic medical center implemented the BioFire(®) FilmArray(®) Meningitis/Encephalitis Panel (MEP), which detects 14 viral, bacterial, and fungal pathogens. Institutional guidelines recommended the test be used in nonimmunocompromised patients age ≥2 years only if the cereb...

Descripción completa

Detalles Bibliográficos
Autores principales: McCreery, Randy, Nielsen, Lindsey E, Clarey, Dillon, Murphy, Caitlin N, Van Schooneveld, Trevor C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809276/
http://dx.doi.org/10.1093/ofid/ofz359.084
_version_ 1783461946469646336
author McCreery, Randy
Nielsen, Lindsey E
Clarey, Dillon
Murphy, Caitlin N
Van Schooneveld, Trevor C
author_facet McCreery, Randy
Nielsen, Lindsey E
Clarey, Dillon
Murphy, Caitlin N
Van Schooneveld, Trevor C
author_sort McCreery, Randy
collection PubMed
description BACKGROUND: In 2016, our academic medical center implemented the BioFire(®) FilmArray(®) Meningitis/Encephalitis Panel (MEP), which detects 14 viral, bacterial, and fungal pathogens. Institutional guidelines recommended the test be used in nonimmunocompromised patients age ≥2 years only if the cerebrospinal fluid (CSF) white blood cell (WBC) count was >10 cells/mm(3). METHODS: We reviewed all MEP performed at our institution over 2 years (January 1, 2017 to December 31, 2018). We collected CSF WBC count, protein, and glucose; MEP results; CSF culture results; and demographics. We excluded children age <2 years, immunocompromised patients, those without a CSF WBC count, and duplicate tests during the same illness. RESULTS: Of 453 patients, 311 met inclusion criteria. The median age was 51, 51% male. Median CSF indices: WBC/mm(3) = 4, protein = 57 mg/dL, glucose = 66 mg/dL. MEP positivity rate = 12% (37/311): viruses (29/37), bacteria (7/37), and fungi (1/37). Positive bacterial/fungal MEP results compared with CSF culture are summarized in Table 1. No clinically significant discordant negative MEP results occurred compared with CSF culture, cryptococcal antigen, or other viral PCR testing. Of the 311 patients, 184 (59%) had ≤10 CSF WBC/mm(3). Of these, 4 had positive MEP results: 1 enterovirus, 1 human herpes virus 6 (HHV-6) and 2 varicella zoster virus (VZV). The HHV-6 was judged clinically insignificant. The 2 VZV cases had concomitant shingles and were already on acyclovir. No clinically significant MEP results occurred in 110/311 (35%) patients with ≤ 2 CSF WBC/mm(3). CONCLUSION: In nonimmunocompromised patients, age ≥ 2, with ≤ 10 CSF WBC/mm(3) on lumbar puncture, positive MEP results were rare and the clinical significance of the 4 positives was debatable. A hard-stop restriction in this setting could have reduced overall use by up to 59% and resulted in significant cost savings. Lower CSF WBC/mm(3) cut-offs could be considered and still improve MEP utilization. [Image: see text] DISCLOSURES: All Authors: No reported Disclosures.
format Online
Article
Text
id pubmed-6809276
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68092762019-10-28 1821. Evaluation of Cerebrospinal Fluid White Blood Cell Count Criteria for Use of the BioFire(®) FilmArray(®) Meningitis/Encephalitis Panel in Immunocompetent Patients McCreery, Randy Nielsen, Lindsey E Clarey, Dillon Murphy, Caitlin N Van Schooneveld, Trevor C Open Forum Infect Dis Abstracts BACKGROUND: In 2016, our academic medical center implemented the BioFire(®) FilmArray(®) Meningitis/Encephalitis Panel (MEP), which detects 14 viral, bacterial, and fungal pathogens. Institutional guidelines recommended the test be used in nonimmunocompromised patients age ≥2 years only if the cerebrospinal fluid (CSF) white blood cell (WBC) count was >10 cells/mm(3). METHODS: We reviewed all MEP performed at our institution over 2 years (January 1, 2017 to December 31, 2018). We collected CSF WBC count, protein, and glucose; MEP results; CSF culture results; and demographics. We excluded children age <2 years, immunocompromised patients, those without a CSF WBC count, and duplicate tests during the same illness. RESULTS: Of 453 patients, 311 met inclusion criteria. The median age was 51, 51% male. Median CSF indices: WBC/mm(3) = 4, protein = 57 mg/dL, glucose = 66 mg/dL. MEP positivity rate = 12% (37/311): viruses (29/37), bacteria (7/37), and fungi (1/37). Positive bacterial/fungal MEP results compared with CSF culture are summarized in Table 1. No clinically significant discordant negative MEP results occurred compared with CSF culture, cryptococcal antigen, or other viral PCR testing. Of the 311 patients, 184 (59%) had ≤10 CSF WBC/mm(3). Of these, 4 had positive MEP results: 1 enterovirus, 1 human herpes virus 6 (HHV-6) and 2 varicella zoster virus (VZV). The HHV-6 was judged clinically insignificant. The 2 VZV cases had concomitant shingles and were already on acyclovir. No clinically significant MEP results occurred in 110/311 (35%) patients with ≤ 2 CSF WBC/mm(3). CONCLUSION: In nonimmunocompromised patients, age ≥ 2, with ≤ 10 CSF WBC/mm(3) on lumbar puncture, positive MEP results were rare and the clinical significance of the 4 positives was debatable. A hard-stop restriction in this setting could have reduced overall use by up to 59% and resulted in significant cost savings. Lower CSF WBC/mm(3) cut-offs could be considered and still improve MEP utilization. [Image: see text] DISCLOSURES: All Authors: No reported Disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809276/ http://dx.doi.org/10.1093/ofid/ofz359.084 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
McCreery, Randy
Nielsen, Lindsey E
Clarey, Dillon
Murphy, Caitlin N
Van Schooneveld, Trevor C
1821. Evaluation of Cerebrospinal Fluid White Blood Cell Count Criteria for Use of the BioFire(®) FilmArray(®) Meningitis/Encephalitis Panel in Immunocompetent Patients
title 1821. Evaluation of Cerebrospinal Fluid White Blood Cell Count Criteria for Use of the BioFire(®) FilmArray(®) Meningitis/Encephalitis Panel in Immunocompetent Patients
title_full 1821. Evaluation of Cerebrospinal Fluid White Blood Cell Count Criteria for Use of the BioFire(®) FilmArray(®) Meningitis/Encephalitis Panel in Immunocompetent Patients
title_fullStr 1821. Evaluation of Cerebrospinal Fluid White Blood Cell Count Criteria for Use of the BioFire(®) FilmArray(®) Meningitis/Encephalitis Panel in Immunocompetent Patients
title_full_unstemmed 1821. Evaluation of Cerebrospinal Fluid White Blood Cell Count Criteria for Use of the BioFire(®) FilmArray(®) Meningitis/Encephalitis Panel in Immunocompetent Patients
title_short 1821. Evaluation of Cerebrospinal Fluid White Blood Cell Count Criteria for Use of the BioFire(®) FilmArray(®) Meningitis/Encephalitis Panel in Immunocompetent Patients
title_sort 1821. evaluation of cerebrospinal fluid white blood cell count criteria for use of the biofire(®) filmarray(®) meningitis/encephalitis panel in immunocompetent patients
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809276/
http://dx.doi.org/10.1093/ofid/ofz359.084
work_keys_str_mv AT mccreeryrandy 1821evaluationofcerebrospinalfluidwhitebloodcellcountcriteriaforuseofthebiofirefilmarraymeningitisencephalitispanelinimmunocompetentpatients
AT nielsenlindseye 1821evaluationofcerebrospinalfluidwhitebloodcellcountcriteriaforuseofthebiofirefilmarraymeningitisencephalitispanelinimmunocompetentpatients
AT clareydillon 1821evaluationofcerebrospinalfluidwhitebloodcellcountcriteriaforuseofthebiofirefilmarraymeningitisencephalitispanelinimmunocompetentpatients
AT murphycaitlinn 1821evaluationofcerebrospinalfluidwhitebloodcellcountcriteriaforuseofthebiofirefilmarraymeningitisencephalitispanelinimmunocompetentpatients
AT vanschooneveldtrevorc 1821evaluationofcerebrospinalfluidwhitebloodcellcountcriteriaforuseofthebiofirefilmarraymeningitisencephalitispanelinimmunocompetentpatients